• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Nov. 1 Aurobindo Pharma Ltd posted a loss of Rs 38.50 crore in the second quarter ended September 30, 2008, compared with a Rs 100-crore profit in the corresponding quarter of previous financial year.

This was due to a forex loss of Rs 105 crore including loss due to restatement of foreign currency convertible bonds (FCCBs) of Rs 85.30 crore.

The total income, however, increased marginally to Rs 635 crore (Rs 630 crore). This was driven by the increase in formulation sales by 33.3 per cent to Rs. 319 crore.

The earnings per share turned negative at (-) Rs 7.16 as against earnings or Rs 18.80 in the year-ago period. During the quarter under review, the Hyderabad-based company filed five abbreviated new drug applications, and three drug master files in the US, according to a release.

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line